Table 2 Distribution of participants by WHO-staging, CD4 count and initial ART regimens
Male | Female | Total | |||||
|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||
WHO clinical staging | I | 80 | 11.5% | 274 | 18.6% | 354 | 16.4% |
II | 86 | 12.4% | 204 | 13.9% | 290 | 13.4% | |
III | 416 | 60.0% | 863 | 58.7% | 1279 | 59.1% | |
IV | 111 | 16.0% | 129 | 8.8% | 240 | 11.1% | |
Total | 693 | 100.0% | 1470 | 100.0% | 2163 | 100.0% | |
CD4 count | 0 to 350 | 737 | 89.0% | 1541 | 85.9% | 2278 | 86.9% |
351 to 500 | 59 | 7.1% | 164 | 9.1% | 223 | 8.5% | |
>500 | 32 | 3.9% | 88 | 4.9% | 120 | 4.6% | |
Total | 828 | 100.0% | 1793 | 100.0% | 2621 | 100.0% | |
Initial ART regiments | AZT/3TC/EFV | 142 | 13.1% | 292 | 12.9% | 434 | 13.0% |
AZT/3TC/NVP | 347 | 32.0% | 710 | 31.3% | 1057 | 31.6% | |
TDF/3TC/EFV | 489 | 45.2% | 986 | 43.5% | 1475 | 44.0% | |
TDF/3TC/NVP | 60 | 5.5% | 192 | 8.5% | 252 | 7.5% | |
Others | 45 | 4.2% | 86 | 3.8% | 131/ | 3.9% | |
Total | 1083 | 100.0% | 2266 | 100.0% | 3349 | 100.0% | |